Compare NTRS & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTRS | WAT |
|---|---|---|
| Founded | 1889 | 1958 |
| Country | United States | United States |
| Employees | 23800 | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8B | 33.6B |
| IPO Year | N/A | 1996 |
| Metric | NTRS | WAT |
|---|---|---|
| Price | $160.47 | $353.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $163.55 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 1.1M | 974.9K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | N/A | ★ 10.76 |
| Revenue | N/A | ★ $3,165,286,000.00 |
| Revenue This Year | $8.40 | $104.66 |
| Revenue Next Year | $4.13 | $10.40 |
| P/E Ratio | ★ $16.88 | $32.44 |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $104.09 | $275.05 |
| 52 Week High | $173.19 | $414.15 |
| Indicator | NTRS | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 66.08 |
| Support Level | $135.49 | $284.02 |
| Resistance Level | $173.19 | $397.85 |
| Average True Range (ATR) | 4.38 | 12.67 |
| MACD | -1.25 | 4.61 |
| Stochastic Oscillator | 7.26 | 94.14 |
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2025, Northern Trust had assets under custody or administration of $18.7 trillion and assets under management of $1.8 trillion.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.